Pharmaceutical Technology North America, APIs, Excipients, and Manufacturing 2019 Supplement (PDF)

The reduction is expected to be “substantially completed,” the San Diego-based company said, in the second quarter of 2025.

This episode is a compilation of comments taken from a series of interviews where experts are discussing how AI might impact the global bio/pharma industry in the future.

The platform is live with full functionality for use by marketing authorization holders and national competent authorities to report drug supply information.

In this podcast episode, we discuss trends in dosage forms, specifically oral solid dosage, as viewed by five industry experts who recently exhibited at CPHI Milan.

Data from a Phase III study that evaluated lazertinib, in combination with amivantamab, in comparison to osimertinib as a first-line treatment resulted in the EC’s decision.

The company’s investments in Canada since 2023 have now resulted in the creation, or potential thereof, of 1200 new job positions.